RX Patient Tools
Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.
Methoxsalen Oral /Methoxsalen is a naturally occurring substance isolated from the seeds of the plant Ammi majus with photoactivation properties. As a member of the family of compounds known as psoralens or furocoumarins, methoxsalen’s exact mechanism of action is unknown; upon photoactivation, methoxsalen has been observed to bind covalently to and crosslink DNA.
Methoxsalen is a member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 positions is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis. It has a role as a dermatologic drug, an antineoplastic agent, a photosensitizing agent, a cross-linking reagent and a plant metabolite. It is a member of psoralens and an aromatic ether. It derives from a psoralen.
Synonyms
- Ammoidin
- Methoxsalen
-
Méthoxsalène
-
Metoxaleno
-
O-methylxanthotoxol
- Xanthotoxin
- Xanthotoxine
Mechanism of Action of Methoxsalen
After activation it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.
Methoxsalen, when activated by long-wavelength UV light in the range of 320-400 nm, is strongly entheogenic, melanogenic, and cytotoxic in the epidermis; the maximal entheogenic activity occurs in the range of 330-360 nm. The mechanisms of action of methoxsalen in inducing repigmentation of vitiliginous skin have not been established. Repigmentation depends on the presence of functioning melanocytes and UV light. Methoxsalen may activate the few functional and dihydroxyphenylalanine-positive melanocytes present in vitiliginous skin. An increase in the activity of tyrosinase, the enzyme that catalyzes the conversion of tyrosine to dihydroxyphenylalanine (a precursor of melanin), has been shown in melanin-producing cells exposed in vitro to trioxsalen and UVA light. In addition, binding of photoactivated psoralens (in triplet states) to pyrimidine bases of nucleic acids, with subsequent inhibitions of DNA synthesis, cell division, and epidermal turnover, has been demonstrated. Following photoactivation, methoxsalen forms covalent bonds with DNA to produce monofunctional (addition to a single strand of DNA) and bifunctional adducts (crosslinking to both strands of DNA). Reactions with other proteins also occur. Psoralens may also increase melanin formation by producing an inflammatory reaction in the skin. Other mechanisms of increased pigmentation may include an increase in the number of functional melanocytes (and possibly activation of dormant melanocytes); enhancement of melanin granule synthesis; stimulation of the movement of melanocytes up hair follicles resulting in melanocytic repopulation of the epidermis; and/or hypertrophy of melanocytes and increased arborization of their dendrites.
Indications of Methoxsalen
- For the treatment of psoriasis and vitiligo
- Treatment of Graft-versus-Host disease.
- Idiopathic Vitiligo
- Refractory peripheral cutaneous T-cell lymphoma
- Severe Psoriasis
- For the treatment of psoriasis and vitiligo
Contraindications of Methoxsalen
- malignant melanoma
- a type of skin cancer
- squamous cell carcinoma
- Absence of Pigment in the Skin
- Hair and Eyes
- porphyria
- porphyria cutanea tarda
- erythropoietic protoporphyria
- variegate porphyria
- clouding of the lens of the eye called cataracts
- absent eye lens
- liver problems
- increased sensitivity of the skin to the sun
- Hydro a aciniform
- systemic lupus erythematosus
- an autoimmune disease
- xeroderma pigmentosum
- a mother who is producing milk and breastfeeding
- basal cell carcinoma of the skin
- are allergic to methoxsalen or to any of the ingredients of the medication
- are 12 years of age or younger
- are pregnant or may be pregnant
- are taking medications that increase sensitivity to sunlight
- have aphasia
- have a medical condition that increases sensitivity to sunlight (such as porphyria, lupus, or infectious leukoderma)
- have poor liver function
Dosage of Methoxsalen
Strengths: 10 mg; 20 mcg/mL
Psoriasis
Soft gelatin capsules
Initial dose: Take capsules orally 1.5 to 2 hours before UVA exposure with some low-fat food or milk according to patient weight: Weight soft gelatin capsule dose
- Under 30 kg: 10 mg
- 30 to 50 kg: 20 mg
- 51 to 65 kg: 30 mg
- 66 to 80 kg: 40 mg
- 81 to 90 kg: 50 mg
- 91 to 115 kg: 60 kg
- Over 115 kg: 70 mg
Psoriasis
Soft gelatin capsules
Initial dose: Take capsules orally 1.5 to 2 hours before UVA exposure with some low fat food or milk according to patient weight
- Weight: soft gelatin capsule dose
- Under 30 kg: 10 mg
- 30 to 50 kg: 20 mg
- 51 to 65 kg: 30 mg
- 66 to 80 kg: 40 mg
- 81 to 90 kg: 50 mg
- 91 to 115 kg: 60 kg
- Over 115 kg: 70 mg
Cutaneous T-cell Lymphoma
Extracorporeal administration
- Treatment involves the collection of leukocytes, photoactivation, and reinfusion of photoactivated cells.
- Medication should be injected into the photopheresis system, not directly into patients.
- Dosage is calculated for each treatment according to the treatment volume.
- Treatment volume x 0.017 = mL of Uvadex(R) for each treatment
- Normal treatment schedule: Treatment is given on 2 consecutive days every 4 weeks for a minimum of 7 treatment cycles (6 months)
- Accelerated treatment schedule: If patient assessment during the 4th treatment cycle (about 3 months) shows an increased skin score from baseline, treatment frequency may be increased to 2 consecutive treatments every 2 weeks.
- If a 25% improvement in skin score is attained after 4 weeks, the normal treatment schedule may be resumed.
- Patients maintained on accelerated treatment may receive a maximum of 20 cycles.
- Duration of therapy: 6 months
Drug Interactions of Methoxsalen Oral
Methoxsalen may interact with following drugs, supplements, & may change the efficacy of a drug
- anticoagulants (e.g., warfarin, heparin)
- medications that make the skin more sensitive to sunlight (e.g., hydrochlorothiazide, ciprofloxacin, coal tar)
- other medications that are applied to the skin
- duloxetine
- emtricitabine
- High Potency B Complex with B12 and C (multivitamin)
- lopinavir
- ritonavir
- arginine
- atropine
- diphenoxylate
- acetaminophen
- peginterferon alfa-2a
- thyrotropin alpha
- fluocinolone
- hydroquinone
- tretinoin topical
- abacavir
- lamivudine
- zidovudine
- emtricitabine
- tenofovir
- sildenafil
- Vitamin D3 (cholecalciferol)
- rivaroxaban
Pregnancy Category of Methoxsalen Oral
Pregnancy
The safety of this medication for use while pregnant has not been established. It should not be used during pregnancy unless, in the judgment of the doctor, the benefits outweigh the risks.
Lactation
No information is available on the use of methoxsalen during breastfeeding. Expert opinion indicates that due to the photosensitizing effects of methoxsalen, breastfeeding should be withheld for 24 hours after an oral dose to allow for 95% of the drug to be eliminated in the mother’s urine. The same precaution probably applies to patients receiving methoxsalen as a part of therapy for cutaneous T-cell lymphoma. Use of topical methoxsalen is not contraindicated during breastfeeding, but avoid direct contact of the treated skin with the skin of the infant. The safety of this medication for use while breastfeeding has not been established. It should not be used while breast-feeding unless, in the judgment of the doctor, the benefits outweigh the risks.
References
